PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
// Etay Ziv 1 , Michael Bergen 2 , Hooman Yarmohammadi 1 , F. Ed Boas 1 , E. Nadia Petre 1 , Constantinos T. Sofocleous 1 , Rona Yaeger 3 , David B. Solit 4, 5, 6 , Stephen B. Solomon 1 , Joseph P. Erinjeri 1 1 Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA 2 Department of Radiology, Mount Sinai Hospital, New York, USA 3 Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA 4 Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA 5 Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA 6 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA Correspondence to: Etay Ziv, email: zive@mskcc.org Keywords: biomarkers, colorectal, PI3K, radioembolization, MAPK Received: August 25, 2016 Accepted: January 16, 2017 Published: February 11, 2017 ABSTRACT Purpose : To establish the relationship between common mutations in the MAPK and PI3K signaling pathways and local progression after radioembolization. Materials and Methods : Retrospective review of a HIPAA-compliant institutional review-board approved database identified 40 patients with chemo-refractory colorectal liver metastases treated with radioembolization who underwent tumor genotyping for hotspot mutations in 6 key genes in the MAPK/PI3K pathways (KRAS, NRAS, BRAF, MEK1, PIK3CA, and AKT1). Mutation status as well as clinical, tumor, and treatment variables were recorded. These factors were evaluated in relation to time to local progression (TTLP), which was calculated from time of radioembolization to first radiographic evidence of local progression. Predictors of outcome were identified using a proportional hazards model for both univariate and multivariate analysis with death as a competing risk. Results : Sixteen patients (40%) had no mutations in either pathway, eighteen patients (45%) had mutations in the MAPK pathway, ten patients (25%) had mutations in the PI3K pathway and four patients (10%) had mutations in both pathways. The cumulative incidence of progression at 6 and 12 months was 33% and 55% for the PI3K mutated group compared with 76% and 92% in the PI3K wild type group. Mutation in the PI3K pathway was a significant predictor of longer TTLP in both univariate (p=0.031, sHR 0.31, 95% CI: 0.11-0.90) and multivariate (p=0.015, sHR=0.27, 95% CI: 0.096-0.77) analysis. MAPK pathway alterations were not associated with TTLP. Conclusions : PI3K pathway mutation predicts longer time to local progression after radioembolization of colorectal liver metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Despite these improvements, patients with mutations in downstream effectors of the EGFR signaling pathway may not respond to these anti-EGFR antibodies [3].”
BackgroundMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119 · cited 1×
“), where samples are tested in duplicate using multiplexed assays to interrogate mutations in hotspots of KRAS, BRAF, NRAS, MEK1, PIK3CA, and AKT1[36] or (b) a previously reported hybridization capture-based next generation sequencing assay for targeted deep sequencing of all exons and selected introns of key cancer g…”
BackgroundThe Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
Yaeger, R., Cowell, E., Chou, J. F., Gewirtz, A. N., Borsu, L., Vakiani, E., Solit, D. B., Rosen, N., Capanu, M., Ladanyi, M., et al. (2015) · Cancer · doi:10.1002/cncr.29196 · Cited by 187
Self-citation
Cited by
Van den Eynde, M., Mlecnik, B., Bindea, G., Fredriksen, T., Church, S. E., Lafontaine, L., Haicheur, N., Marliot, F., Angelova, M., Vasaturo, A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.003 · Cited by 281
Liquid biopsy for cancer: review and implications for the radiologist
Underwood, J. J., Quadri, R. S., Kalva, S. P., Shah, H., Sanjeeviah, A. R., Beg, M. S., & Sutphin, P. D. (2020) · Radiology · doi:10.1148/radiol.2019182584 · Cited by 87
PIK3CA mutation and colorectal cancer precision medicine
Hamada, T., Nowak, J. A., & Ogino, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15724 · Cited by 29
Metadata
- Authors
- Ziv, E., Bergen, M., Yarmohammadi, H., Boas, F. E., Petre, E. N., Sofocleous, C. T., Yaeger, R., Solit, D. B., Solomon, S. B., & Erinjeri, J. P.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-02-11
- Volume
- 8
- Issue
- 14
- Pages
- 23529-23538
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2588199348
- Cited by
- 35
- References
- 4
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. https://app.cochat.ai/papers/10.18632/oncotarget.15278
- The paper
- Ziv, E., Bergen, M., Yarmohammadi, H., Boas, F. E., Petre, E. N., Sofocleous, C. T., Yaeger, R., Solit, D. B., Solomon, S. B., & Erinjeri, J. P. (2017). PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. Oncotarget. https://doi.org/10.18632/oncotarget.15278
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.